Hormone receptor-positive HER2-low metastatic breast cancer (mBC): evolution of HER2 status after CDK4/6 inhibitor treatment

被引：0
|
作者：
de Nonneville, Alexandre
Finetti, Pascal
Boudin, Laurys
Usclade, Lucas
Mescam, Lenaig
Durieux, Emeline
Boucraut, Agathe
Viret, Frederic
Mamessier, Emilie
Goncalves, Anthony
Bertucci, Francois
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO4-05-06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO4-05-06
引用
收藏
页数：3
相关论文
共 50 条
  • [1] The association of HER2 low expression with the efficacy of CDK4/6 inhibitor in hormone receptor positive HER2 negative metastatic breast cancer.
    Bao, Kelvin K. H.
    Sutanto, Leone
    Tse, Shirley S. W.
    Cheung, Ka Man
    Chan, Jeffrey C. H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Efficacy of first line CDK4/6 inhibitors in HER2-low vs HER2-zero, hormone receptor positive, HER2 negative metastatic breast cancer
    Sanchez-Bayona, Rodrigo
    Teran, Santiago
    De Torre, Ana Sanchez
    Alva, Manuel
    Lema, Laura
    Manso, Luis
    Toledo, Estefania
    Roncero, Ana Maria
    Merino, Cristina
    Martinez, Mario
    Parrilla, Lucia
    Ciruelos, Eva
    Tolosa, Pablo
    [J]. CANCER RESEARCH, 2022, 82 (04)
  • [3] CDK4/6-Inhibitors Inclusion in the Treatment of metastatic Hormone Receptor-positive, HER2-negative Breast Cancer
    Forstmeyer, D.
    [J]. ONKOLOGE, 2016, 22 (07): : 507 - 508
  • [4] The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
    Grinshpun, Albert
    Tolaney, Sara M. M.
    Burstein, Harold J. J.
    Jeselsohn, Rinath
    Mayer, Erica L. L.
    [J]. NPJ BREAST CANCER, 2023, 9 (01)
  • [5] The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
    Albert Grinshpun
    Sara M. Tolaney
    Harold J. Burstein
    Rinath Jeselsohn
    Erica L. Mayer
    [J]. npj Breast Cancer, 9
  • [6] Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm
    Boyle, Frances
    Beith, Jane
    Burslem, Katie
    de Boer, Richard
    Hui, Rina
    Lim, Elgene
    McCarthy, Nicole
    Redfern, Andrew
    Woodward, Natasha
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 3 - 11
  • [7] Clinical effectiveness of CDK4/6 inhibitors in HER2-low metastatic breast cancer
    Zhang, Frank
    Mesias, Jesus Anampa
    [J]. CANCER RESEARCH, 2024, 84 (09)
  • [8] The Prognostic Value of Low HER2 Expression on Treatment Outcomes in Metastatic Hormone Receptor-positive Breast Cancer Patients Treated with CDK4/6 Inhibitors and Endocrine Therapy
    Muhammad, R.
    Mumtaz, S.
    Goyal, N.
    Konstantis, A.
    [J]. CLINICAL ONCOLOGY, 2024, 36 (04) : E110 - E110
  • [9] The association of hormone receptor expression level and clinical efficacy of CDK4/6 inhibitor in hormone receptor-positive, HER2-negative metastatic breast cancer
    Bao, Kelvin K. H.
    Wong, Carol H. Y.
    Yung, Jackie
    Tam, Venus
    Cheung, Ka Man
    Chan, Jeffrey C. H.
    Yiu, Harry H. Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] Differences in Treatment Outcomes Between Patients with HER2-Low versus HER2-Zero, Hormone Receptor-Positive Advanced-Stage Breast Cancer Treated with CDK4/6 Inhibitors
    Sharaf, Baha'
    Abu-Fares, Hala
    Tamimi, Faris
    Al-Sawajneh, Suhaib
    Salama, Osama
    Daoud, Rand
    Alhajahjeh, Abdulrahman A.
    Al-Lababidi, Sawsan
    Abdel-Razeq, Hikmat
    [J]. CANCER RESEARCH, 2023, 83 (05)
12345